Contrast agents and radiopharmaceuticals are a high-growth, high-margin adjacency to diagnostic imaging equipment with distinct competitive dynamics. GE HealthCare's Pharmaceutical Diagnostics segment — $2.9 billion in 2025 growing at 15.6% — is the fastest-growing business in the company, driven by the launch of new PET tracers and the theranostics commercial momentum. Novel radiopharmaceuticals for amyloid PET imaging, PSMA PET for prostate cancer, and DOTATATE for neuroendocrine tumors are creating new clinical and commercial categories.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• MRI Contrast Agents — Gadolinium, Iron Oxide
• CT Contrast Agents
• PET Tracers — FDG, Amyloid, PSMA, DOTATATE
• Theranostic Agents
• Radiopharmaceutical Supply Chain
• Regulatory Pathway
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Technology Landscape Overview
3. MRI Contrast Agents — Gadolinium, Iron Oxide
4. CT Contrast Agents
5. PET Tracers — FDG, Amyloid, PSMA, DOTATATE
6. Theranostic Agents
7. Radiopharmaceutical Supply Chain
8. Regulatory Pathway
9. Competitive Landscape
10. Competitive Landscape
11. Strategic Conclusions and Recommendations
12. Appendix
List of Tables
Table 1. Technology Overview and Key Data 2025
Table 2. MRI Contrast Agents
Table 3. CT Contrast Agents
Table 4. PET Tracers
Table 5. Theranostic Agents
Table 6. Radiopharmaceutical Supply Chain
Table 7. Regulatory Pathway
Table 8. Competitive Landscape
Table 9. Leading Companies — Technology Investment and Strategy 2025
Table 10. M&A and Partnership Activity 2023-2025
Table 11. Key Risks and Mitigation Strategies
Companies Profiled
Bayer
Cardinal Health
GE HealthCare
Lantheus
Novartis AAA
POINT Biopharma
Siemens Healthineers
